The 2021 Hurun Report is released!

On October 27, the Hurun Research Institute released the "2021 Hurun Rich List"
.

This year, the number of Hurun Reports has expanded by 22%, an increase of 520 from 2,398 last year.

Zhong Sui-sui sold water and medicine, and became the richest man in China with 390 billion yuan, an increase of 25 billion yuan from last year; Douyin founder Zhang Yiming surpassed Ma Huateng and Ma Yun, ranking second with 340 billion yuan; Ningde era Zeng Yuqun entered the top for the first time Third, wealth has increased by 200 billion yuan; fourth and fifth are Tencent's Ma Huateng and Alibaba's Jack Ma respectively.
Their wealth has fallen by 73 billion yuan and 145 billion yuan respectively from last year
.

In this year's Hurun Report, manufacturing, healthcare, real estate, chemicals, and financial investment are the top five sources of wealth for entrepreneurs on the list
.

Among them, the pharmaceutical industry has 12 people on the list, involving 10 companies

Data from: 2021 Hurun Report

01 Zhong Sui Sui·Health Hall

01 Zhong Sui Sui·Health Hall

Zhong Sui Sui owns two listed companies-Wantai Bio and Nongfu Spring.
Among them, Wantai Bio is affiliated to Yangshengtang and is mainly engaged in the development, production and sales of in vitro diagnostic reagents, automated testing equipment, and vaccines
.

At present, the company's product line has a full set of HIV (HIV), hepatitis B virus (HBV), hepatitis C virus (HCV), hepatitis E virus (HEV), syphilis (TP, TRUST), rotavirus (RV), T lymphocyte leukemia Enzyme immunoassay and gold-labeled rapid diagnostic reagents for viruses (HTLV), enterovirus 71 (EV71), and influenza A viruses, as well as detection reagents for chemiluminescence, nucleic acid, clinical biochemistry, and clinical laboratory quality control products, vaccines, etc.

According to the 2021 semi-annual report of Wantai Biotechnology, the company’s operating income in the first half of the year was 1.
964 billion yuan, a year-on-year increase of 132.
78%; the net profit attributable to shareholders of listed companies was 722 million yuan, a year-on-year increase of 195.
92%; The net profit from recurring gains and losses was 692 million yuan, a year-on-year increase of 202.
45%; the net cash flow from operating activities was 377 million yuan, a year-on-year increase of 213.
44%
.

02 Jiang Rensheng Family · Zhifei Biology

02 Jiang Rensheng Family · Zhifei Biology

Zhifei was established in 1995.
The company distributes AC group meningococcal conjugate vaccine, ACY W135 group meningococcal vaccine, type B Haemophilus influenzae conjugate vaccine, freeze-dried live attenuated hepatitis A vaccine, microcards, etc.
, marketing network Covering 31 provinces/autonomous regions/municipalities and cities across the country
.

On August 30, Zhifei Biological disclosed its 2021 semi-annual report, with a net profit of 5.
491 billion yuan, a year-on-year increase of 264.
94%, far exceeding the full-year net profit of 3.
301 billion yuan in 2020
.

As of the first half of the year, Zhifei Bio has 10 products on sale, and 1 product is used for emergency use, including vaccine products to prevent infectious diseases such as meningitis, cervical cancer, and pneumonia, covering those that provide effective solutions for the diagnosis, prevention, and treatment of tuberculosis infection.

On August 27, Zhifei Biological issued an announcement stating that its wholly-owned subsidiary Zhifei Longkoma Biopharmaceuticals and the Institute of Microbiology of the Chinese Academy of Sciences jointly developed a recombinant new coronavirus vaccine (CHO cell) to obtain key data from phase III clinical trials.
, The preliminary analysis results show: the protective effect of Alpha mutant strain is 92.
93%; the protective effect of Delta mutant strain is 77.
54%
.

03 Chen Bang Aier Ophthalmology

03 Chen Bang Aier Ophthalmology

Aier Ophthalmology is a leading private ophthalmology company.
On October 25, the company announced its third quarterly results announcement.
The report showed that the company achieved 11.
596 billion yuan in revenue in the first three quarters, a year-on-year increase of 35.
38%; net profit attributable to the parent was 2.
003 billion yuan, a year-on-year increase An increase of 29.
59%; of which revenue in the third quarter was 4.
248 billion yuan, a year-on-year decrease of 3.
48%; net profit attributable to parent company was 888 million yuan, a year-on-year increase of 2.
05%; non-net profit was 948 million yuan, a year-on-year decrease of 5.
38%
.

Since its listing, Aier Ophthalmology has conducted frequent expansion activities focusing on mergers and acquisitions.
In 2021, it has planned to acquire 13 hospitals
.

In June of this year, Aier Ophthalmology announced that it intends to acquire part of Dandong Aier, Linyi Aier and Wanzhou Aier.
Among them, the acquisition of 55% of the shares of Dandong Aier Hospital held by Hunan Liangshi Changyin Medical Co.
, Ltd.
The transaction price is 34.
595 million yuan.
, Linyi Aier Hospital’s 51% equity transaction price was 37.
944 million yuan, and Wanzhou Aier Hospital’s 80% equity transaction price was 64.
64 million yuan
.

In August, Aier Ophthalmology announced again that it intends to acquire 55% of Rizhao Aier, 51% of Weihai Aier, 75% of Heyuan Aier, 65.
1% of Jiangmen Xinhui Aier and Zao 70% equity of Yangaier
.

In October, Aier Ophthalmology announced again that it intends to acquire 5 target hospitals
.

Among them, Aier Ophthalmology will acquire 55% of Anshan Aier, 51% of Cangzhou Aier, 51% of Fuyang Aier, 72.

04 Xu Hang, Li Xiting·Mindray Medical

04 Xu Hang, Li Xiting·Mindray Medical

Mindray Medical was established in 1991 and is mainly engaged in the research and development and manufacturing of clinical medical equipment.
Its product areas cover life information and support, clinical testing and reagents, digital ultrasound, and radiological images
.

Recently, Mindray Medical disclosed the third quarter report that the company achieved operating income of 19.
392 billion yuan in the first three quarters of 2021, an increase of 20.
72% over the same period last year, and realized a net profit of 6.
663 billion yuan attributable to shareholders of listed companies, an increase of 24.
23% over the same period last year
.

Among them, the operating income in the third quarter was 6.

In the latest issue of "Investor Relations Activity Record" published by Mindray Medical a few days ago, it is stated that benefiting from centralized procurement and new infrastructure expansion, the company will continue to gain growth drivers in the next three years
.

In addition, in terms of products, Mindray Medical hopes to make most of its IVD and medical imaging products enter the world-class echelon within three years

05 Xu Haoyu Family Yangtze River Pharmaceutical

05 Xu Haoyu Family Yangtze River Pharmaceutical

Yangtze River Pharmaceutical was founded in 1971, the development so far, the layout of the enterprise involved in many areas of medicine, Chinese medicine, medical equipment, health food, food, well-known drugs have Lanqin oral, Bailemian capsule, astragalus and other fine
.

As of 2020, the group has 301 products on sale and 314 specifications, covering anesthesia and analgesia, respiratory and anti-allergic, anti-infection, anti-tumor, cardiovascular, and contrast agents

On July 10, Xu Jingren, chairman of Yangtze River Pharmaceutical, died of myocardial infarction during a business trip in Yili, Xinjiang, at the age of 77
.
On July 29, Xu Haoyu, the son of Xu Jingren, was elected as the chairman and legal representative of the company and the general manager of the company
.
On May 13, Xu Jingren/Xu Haoyu ranked 313th in the "2021 New Fortune 500 Rich List" with a fortune of 15 billion yuan
.

On April 15, the State Administration for Market Regulation imposed an administrative penalty on Yangzijiang Pharmaceutical for suspected monopoly
.
According to the audit report provided by Yangzijiang Pharmaceutical, its sales in 2018 were 25.
467 billion yuan, and the parties were fined 3% of 2018 sales, totaling 764 million yuan
.

06 Li Ge, Zhao Ning and WuXi AppTec

06 Li Ge, Zhao Ning and WuXi AppTec

WuXi AppTec was established in 2000 and is the country's most valuable biomedical company with a market value of 450 billion yuan
.
As a billion-dollar market capitalization giant in the CXO industry, the company provides new drug R&D and production services for the global biomedical industry, covering chemical drugs and gene therapy, etc.
Its main business covers CRO, chemical drug CDMO, cell and gene therapy CTDMO and other fields
.

WuXi AppTec's operating income in the first half of this year was 10.
537 billion yuan, a year-on-year increase of 45.
7%; net profit attributable to shareholders of listed companies was 2.
675 billion yuan, a year-on-year increase of 55.
8%; net profit attributable to shareholders of listed companies deducting non-recurring gains and losses was 2.
127 billion Yuan, a year-on-year increase of 88.
05%.
An important factor in revenue growth is the promotion of high-prosperity businesses such as CDMO
.

07 Zhong Huijuan Hansen Pharmaceutical

07 Zhong Huijuan Hansen Pharmaceutical

Hansen Pharma focuses on solid tumors with a high incidence and hematological tumors with relatively limited treatment options.
Its core products include Hengmu Ameile, Pulaile, and Zefei
.
Zhong Huijuan and Hengrui Pharmaceutical Sun Piaoyang are married and have been on the Hurun Report for many years
.

On October 12, Hansen Pharmaceuticals and OliX Pharmaceuticals signed a licensing and cooperation agreement to discover, develop and commercialize siRNA therapies for key targeted indications in China, with a transaction amount of over US$450 million
.

On August 26, Hansen Pharmaceutical announced its 2021 interim results.
The company’s total revenue in the first half of the year was 4.
402 billion yuan, a year-on-year increase of 10.
6%; net profit was 1.
291 billion yuan, a year-on-year increase of 5.
6%; R&D investment was 687 million yuan, a year-on-year increase of 44.
2%.
It accounts for 15.
6% of total revenue.
At present, its main business focuses on anti-tumor, central nervous system diseases, anti-infection and diabetes
.

08 Sun Piaoyang Hengrui Medicine

08 Sun Piaoyang Hengrui Medicine

Hengrui Pharmaceuticals is one of the representatives of China's innovative drug industry.
It is currently in a critical period of corporate transformation.
The company submitted 31 IND applications in the first three quarters and obtained 23 approvals; the number of NDA approved in the first half of the year was as high as 5; Zopali, SHR1701, SHR3680 tablets, pyrrotinib, remazolam, etc.
have been approved for clinical use or included in the proposed breakthrough therapy; the biosimilar drug bevacizumab injection has been approved for three indications
.

In August of this year, Sun Piaoyang, the founder and first chairman of Hengrui Medicine, succeeded Zhou Yunshu and returned to the post of chairman
.
In addition, this year, Henry in transition have conducted License in the project, the introduction of wide-day real biological MIL62, Pune Wanchun Brin Brin and so on
.

On the evening of October 19, Hengrui Medicine disclosed its third-quarter report on the Shanghai Stock Exchange.
In the third quarter, operating income was 6.
901 billion yuan, down 14.
84% year-on-year; net profit attributable to the parent was 1.
54 billion yuan, down 3.
57% year-on-year
.
The main reason for the negative growth in revenue and net profit is that Hengrui's generic drug sales have declined due to the impact of national and local volume purchases
.

09 Zhubao National Clan, Health Yuan

09 Zhubao National Clan, Health Yuan

The company's main business scope covers health care products, chemical preparations, Chinese medicines, chemical raw materials and intermediates, diagnostic reagents and equipment, etc.
Chemical preparations include digestive tract drugs, cardiovascular and cerebrovascular drugs, antimicrobial drugs, anti-tumor drugs, and neurotherapeutic drugs.
, respiratory drugs, etc.
, non-prescription drugs include gastrointestinal drugs "Lizhudele" "Lizhuchangle" and oral ulcer medication "meaning can be attached to" and so on
.

Healthyuan’s third quarter report shows that the company’s revenue in the first three quarters was 11.
934 billion yuan, an increase of 18.
12% year-on-year, and the net profit attributable to shareholders of listed companies was 1.
009 billion yuan, a year-on-year increase of 8.
76%.
Non-net profit was 920 million yuan, a year-on-year increase of 14.
45.
%
.

10 Xie Bing Family Zhongsheng Pharmaceutical

10 Xie Bing Family Zhongsheng Pharmaceutical

Zhongsheng Pharmaceutical is a comprehensive pharmaceutical company whose main products include anti-tumor drugs, liver disease drugs, cardiovascular and cerebrovascular drugs, orthopedic drugs, respiratory system drugs, parenteral nutrition drugs and other products
.
Judging from the first half of this year, anti-tumor drugs, liver disease drugs and cardio-cerebrovascular drugs are the company’s three main forces, with sales revenue of 5.
025 billion yuan, 1.
992 billion yuan and 1.
495 billion yuan, accounting for approximately 35.
0% and 13.
9 billion yuan in revenue.
% And 10.
4%
.
On August 5, the innovative tumor immune drug Peamprizumab injection (trade name: Annikol) was officially approved by the National Medical Products Administration for use in relapsed or refractory classics that have undergone at least second-line system chemotherapy Treatment of adult patients with Hodgkin's lymphoma
.

Judging from Zhongsheng Pharmaceutical’s interim performance, the company’s operating income in the first half of the year was 14.
354 billion yuan, and net profit attributable to its parent was 8.
48 billion yuan, a significant year-on-year increase of 583.
6%; after deducting the huge return on investment in Kexing, the associated companies and joint ventures The company's earnings, net profit attributable to the parent still increased by 22.
9% year-on-year
.

At this time last year, Zhongsheng Pharmaceutical was hit hard by centralized procurement and the epidemic, and its performance suffered Waterloo
.
At the performance briefing meeting held on August 31 this year, Xie Qirun, chairman of the board of directors of China Biopharmaceuticals, pointed out that the company's performance this year has rebounded in an all-round way, and the pressure from centralized procurement and the negative impact of the epidemic have become history
.
The company plans to list nearly a hundred new products within three years, covering multiple therapeutic areas
.